SOPHiA GENETICS holder plans sale of 422 shares

A SOPHiA GENETICS executive filed a Rule 144 notice for a small planned sale of common shares, alongside earlier 10b5-1 sales.

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) received a notice under Rule 144 from Ross J. Muken regarding a proposed sale of 422 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also lists prior Rule 10b5-1 plan sales of common shares in recent months.

Key Figures

Shares proposed for sale: 422 shares Proposed sale value: $3,456.18 Recent 10b5-1 sale shares: 9,838 shares +3 more

6 metrics

Shares proposed for sale 422 shares Common stock covered by the current Rule 144 notice

Proposed sale value $3,456.18 Aggregate value associated with 422 shares in the securities information section

Recent 10b5-1 sale shares 9,838 shares Common stock sold on July 6, 2026 under a 10b5-1 plan

Recent 10b5-1 sale value $51,354.36 Aggregate value of 9,838 shares sold on July 6, 2026

Additional recent sale shares 422 shares Common stock sold on June 22, 2026 under a 10b5-1 plan

Additional recent sale value $2,270.49 Aggregate value of 422 shares sold on June 22, 2026

Key Terms

Rule 144, Restricted Stock Units, 10b5-1 Sales

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 09/18/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for SOPH?

The Form 144 filing discloses that Ross J. Muken has filed a notice of intent to sell 422 shares of SOPHiA GENETICS SA common stock under Rule 144, with the transaction to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

How many SOPH shares are planned to be sold in this Form 144?

The notice covers a proposed sale of 422 shares of SOPHiA GENETICS SA common stock. These shares are associated with Restricted Stock Units and are to be sold for the account of Ross J. Muken.

What is the approximate value of the SOPH shares covered by this Form 144?

The securities information section shows a value of $3,456.18 for the 422 shares of SOPHiA GENETICS SA common stock referenced in the Form 144, indicating the approximate aggregate market value of the planned sale.

Were there other recent SOPH share sales reported for Ross J. Muken?

Yes. In the past three months, the filing lists sales of 9,838 shares of common stock for $51,354.36 on July 6, 2026, and 422 shares for $2,270.49 on June 22, 2026, in each case under a Rule 10b5-1 trading plan.

What type of securities are involved in the SOPH Form 144 filing?

The filing involves common stock of SOPHiA GENETICS SA, including shares tied to Restricted Stock Units. The planned sale of 422 shares and the prior three-month sales all relate to the company’s common shares.

Which broker is handling the SOPH Form 144 sale?

The Form 144 lists Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza in New York, as the broker through which the 422 SOPHiA GENETICS SA shares are to be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:28 PM Accepted by SEC EDGAR 09/21/2026 - 04:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002005463
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SOPHIA GENETICS SA
SEC File Number	001-40627
Address of Issuer	La Piece 12 ch-1180 Rolle SWITZERLAND 00000
Phone	41216941060
Name of Person for Whose Account the Securities are To Be Sold	ROSS J MUKEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	422	3456.18	85127825	09/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/18/2026	Restricted Stock Units	Issuer			422	09/18/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	07/06/2026	9838	51354.36
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	06/22/2026	422	2270.49

144: Remarks and Signature

Remarks
Date of Notice	09/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ross J Muken
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)